| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Head and Neck Imaging |
1 From the Departments of Neurology (K.G., J.B.S., A.K.) and Neuroradiology (U.E., T.N.), University of Tübingen, Tübingen, Germany; Department of Neurology, University of Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany (K.G., A.K.); and Department of Neurology, Friedrich-Schiller-University of Jena, Jena, Germany (C.T.). Received April 14, 2005; revision requested June 14; final revision received August 4; accepted September 1. Address correspondence to A.K. (e-mail: andreas.kastrup{at}medizin.uni-goettingen.de).
Purpose: To retrospectively determine if preprocedural statin treatment is associated with a reduction of cardiovascular events after carotid angioplasty and stent placement (CAS) in patients with symptomatic carotid stenosis.
Materials and Methods: A study resulting in a prospective database was approved by the institutional ethics review board; written informed consent was obtained. The approval and informed consent included future retrospective analysis. Consecutive patients (n = 180) from the prospective database underwent CAS for high-grade symptomatic carotid disease. The frequency of cardiovascular complications (composite of stroke, myocardial infarction, and death within 30 days after CAS) between 127 patients without preprocedural statin treatment and that of 53 patients with preprocedural statin treatment at CAS were compared with 
2 and multivariate logistic regression analysis.
Results: The overall 30-day myocardial infarction rate was two of 180 (1%) patients, the minor stroke rate was 16 of 180 (9%) patients, the major stroke rate was one of 180 (0.5%) patients, and the death rate was two of 180 (1%) patients. The incidence of cardiovascular events (composite of stroke, myocardial infarction, and death within 30 days after CAS) was significantly different between patients with preprocedural treatment (4%) and those without preprocedural statin treatment (15%) (P < .05). These higher complication rates among patients without preprocedural statin treatment were not mediated by adjustment for age, sex, other baseline characteristics, degree of carotid stenosis, use of cerebral protection devices, or the year in which CAS was performed.
Conclusion: Preprocedural statin therapy appears to reduce the incidence of stroke, myocardial infarction, and death within 30 days after CAS. Future prospective randomized trials are warranted to further assess this potential protective effect of statin drugs during carotid interventions.
© RSNA, 2006
This article has been cited by other articles:
|
|
 |
|
  O. O. Zaidat, R. Klucznik, M. J. Alexander, J. Chaloupka, H. Lutsep, S. Barnwell, M. Mawad, B. Lane, M. J. Lynn, M. Chimowitz, et al. The NIH registry on use of the Wingspan stent for symptomatic70-99% intracranial arterial stenosis Neurology, April 22, 2008; 70(17): 1518 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Samuelson, J. Yamamoto, E. I. Levy, A. H. Siddiqui, and L. N. Hopkins The Argument to Support Broader Application of Extracranial Carotid Artery Stent Technology Circulation, October 2, 2007; 116(14): 1602 - 1610. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Groschel, U. Ernemann, J. Larsen, M. Knauth, F. Schmidt, J. Artschwager, and A. Kastrup Preprocedural C-Reactive Protein Levels Predict Stroke and Death in Patients Undergoing Carotid Stenting AJNR Am. J. Neuroradiol., October 1, 2007; 28(9): 1743 - 1746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R Mohler III Carotid stenting for atherothrombosis Heart, September 1, 2007; 93(9): 1147 - 1151. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Pelz, E. I. Levy, and L. N. Hopkins Advances in Interventional Neuroradiology 2006 Stroke, February 1, 2007; 38(2): 232 - 234. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| RADIOLOGY | RADIOGRAPHICS | RSNA JOURNALS ONLINE |
